CRISPR technology has expanded far beyond genome editing with Cas9 to include base editing, prime editing, gene regulation, and diagnostic applications. These advances have transformed molecular biology, biotechnology, and medicine.
Beyond Cas9: The CRISPR Toolbox
CRISPR-Cas systems are adaptive immune systems in bacteria and archaea, and their components have been adapted for diverse applications. Cas9 from Streptococcus pyogenes was the first widely used editing enzyme, creating double-strand breaks guided by a single guide RNA. Cas12a, previously called Cpf1, creates staggered cuts and processes its own pre-crRNA, simplifying multiplexing. Cas13 targets RNA rather than DNA and has collateral cleavage activity. Cas14 targets single-stranded DNA.
CRISPR Interference
Catalytically dead Cas9, which has mutations in both nuclease domains, retains DNA binding but cannot cut. Fusion of dCas9 to repressor domains such as KRAB creates CRISPRi, which silences gene expression by blocking transcription initiation or elongation. Unlike RNA interference, CRISPRi works at the DNA level, producing more complete and specific repression.
CRISPRi is highly specific with minimal off-target effects. It can be used in bacterial and mammalian cells and is reversible when dCas9 expression is turned off. Targeting the promoter or the first few hundred base pairs of the coding sequence produces the strongest repression. Multiplexed CRISPRi with multiple guide RNAs can simultaneously repress several genes.
CRISPR Activation
dCas9 fused to activator domains such as VP64 or VPR creates CRISPRa, which activates endogenous gene expression. The strongest activation uses the synergistic activation mediator system, where multiple activator domains are recruited to the target promoter through antibody-epitope interactions. CRISPRa activates gene expression from the natural genomic context, preserving splicing and regulatory elements.
CRISPRa can activate genes that are otherwise silent in a cell type, enabling functional studies of genes without cloning cDNAs. It has been used to identify genes that confer drug resistance, reprogram cell identity, and screen for genes involved in specific biological processes. CRISPRa screens use guide RNA libraries targeting all known promoters.
Base Editing
Base editing directly converts one DNA base to another without creating a double-strand break. Cytosine base editors fuse a cytidine deaminase to a Cas9 nickase, converting C to T within a 5-nucleotide editing window. Adenine base editors convert A to G using an engineered deaminase. The nickase creates a single-strand nick on the non-edited strand, promoting repair using the edited strand as a template.
Base editing is highly efficient and produces fewer undesired outcomes than Cas9 editing. It cannot introduce arbitrary edits but can correct about 60% of disease-associated point mutations. BE4 and ABE7.10 are optimized base editors with improved efficiency and reduced off-target editing. Base editing has been applied in model organisms, plants, and preclinical gene therapy.
Prime Editing
Prime editing uses a Cas9 nickase fused to a reverse transcriptase, together with a prime editing guide RNA that both specifies the target site and encodes the desired edit. The pegRNA includes a primer binding site and a reverse transcription template containing the edit. After nicking of the target strand, the RT template is used to synthesize edited DNA. Cellular repair pathways incorporate the edited sequence.
Prime editing can install all possible single-nucleotide substitutions, as well as small insertions and deletions, without requiring a double-strand break or donor template. Off-target editing is lower than with Cas9 or base editors. Prime editing efficiencies vary by target site and cell type, and ongoing optimization aims to improve delivery and activity.
CRISPR Diagnostics
Cas12 and Cas13 have collateral cleavage activity: after recognition of their target nucleic acid, they non-specifically cleave nearby single-stranded DNA or RNA. This property has been harnessed for molecular diagnostics. DETECTR uses Cas12a and SHERLOCK uses Cas13 to detect specific nucleic acid sequences.
When the target sequence is present, collateral cleavage of a reporter molecule generates a fluorescent or colorimetric signal. These systems achieve attomolar sensitivity and can distinguish single nucleotide variants. CRISPR diagnostics have been developed for viral detection including SARS-CoV-2, Zika, and dengue, with results read in under an hour without complex equipment.
CRISPR Screening
CRISPR libraries targeting thousands of genes enable genome-scale functional screens. Guide RNA libraries are delivered to a pool of cells, and the effect of each knockout is measured by guide RNA enrichment or depletion using PCR. Positive selection screens identify genes whose knockout confers a growth advantage. Negative selection screens identify genes essential for cell survival. CRISPR screens have higher sensitivity and lower noise than RNAi screens.
